Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 3/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23697044 | 0.80 | SMPD3 (0.34) | KDM4EALDH1A1SMPD3GRM1HPGD | |
| SCHEMBL25098010 | 0.80 | SMPD3 (0.34) | KDM4EALDH1A1SMPD3GRM1HPGD | |
| SCHEMBL10328323 | 0.77 | GRM1 (0.40) | KDM4EALDH1A1GRM1HPGDHTT | |
| SCHEMBL24896144 | 0.77 | GRM1 (0.33) | KDM4EALDH1A1SMPD3GRM1HPGD | |
| SCHEMBL18510385 | 0.77 | ADORA2A (0.46) | ADORA1ADORA2ACDK1DYRK1AGRM1 | |
| SCHEMBL26354798 | 0.77 | PI4KA (0.46) | KDM4EALDH1A1SMPD3GRM1HPGD | |
| SCHEMBL800728 | 0.75 | ADORA1 (0.46) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL17741050 | 0.73 | ADORA1 (0.44) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL16247699 | 0.73 | ADORA1 (0.44) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 | |
| SCHEMBL17729177 | 0.73 | CDK1 (0.44) | ADORA1ADORA2AYTHDC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023108020-A2 | iRNA COMPOSITIONS AND METHODS FOR SILENCING MYLIP | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11649459-B2 | Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2021102373-A1 | ATAXIN3 (ATXN3) RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021087325-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | DNAJC13, DNAJC5, DNAJC7 | ADORA1 4768/4885ADORA2A 4545/4885YTHDC1 433/4885 |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ADAR, SNRPE, ASGR1 | ADORA1 483/4885ADORA2A 270/4885YTHDC1 1368/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | ADORA1 4464/4885ADORA2A 4083/4885YTHDC1 150/4885 |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALK, DGKG, EIF2AK2 | ADORA1 3226/4885ADORA2A 2111/4885YTHDC1 2296/4885 |
| US-11649459-B2 | Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases | SOD1, SOD3, SMN1; SMN2 | ADORA1 1554/4885ADORA2A 987/4885YTHDC1 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.